Pamiparib Application Scope

It is approved in China for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer in patients who have previously undergone two or more lines of chemotherapy.

Pamiparib Characteristics

Ingredients: Pamiparib
Properties: The capsule shell is opaque. The contents are yellow pellets
Packaging Specification: Available Strength: 20 mg/capsule (calculated as C₁₆H₁₅FN₄O); Package Size: 60 capsules per bottle/box
Storage: Store at room temperature (details not explicitly found in sources; general recommendation is 20-25°C)
Expiry Date: To be stated on the specific packaging based on the manufacturing date, typically 24-36 months
Executive Standard: Complies with the quality standards approved by the National Medical Products Administration (NMPA) of China
Approval Number: Approved by the National Medical Products Administration (NMPA) in China
Date of Revision: Approved by the National Medical Products Administration (NMPA) in China
Manufacturer: BeiGene Ltd

Guidelines for the Use of Pamiparib

Dosage and Administration:
- Recommended Dose: 40 mg taken orally twice daily.
- Administration: Swallow capsules whole with or without food.
- Missed Dose: If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double doses.
Adverse Reactions:
- Common Adverse Reactions:
  - Blood and lymphatic system disorders: Anemia, leukopenia, neutropenia, thrombocytopenia, lymphocytopenia.
  - Gastrointestinal disorders: Nausea, vomiting, diarrhea, abdominal pain, decreased appetite.
  - General disorders and administration site conditions: Fatigue.
  - Investigations: Increased AST, increased ALT, increased blood bilirubin.
- Serious Adverse Reactions:
  - Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported with PARP inhibitors.
  - Severe hematological toxicities (e.g., severe anemia, neutropenia, thrombocytopenia).
  - If serious adverse reactions occur, dose interruption, reduction, or discontinuation may be necessary.
Contraindications: Hypersensitivity to pamiparib or any component of the formulation.
Precautions:
- Use with caution in patients with hepatic or renal impairment.
- Not recommended during pregnancy or breastfeeding.
- Effective contraception is advised for women of childbearing potential during and after treatment.

Pamiparib Interactions

CYP3A Inhibitors: Co-administration may increase pamiparib levels, potentially enhancing side effects.
CYP3A Inducers: Co-administration may decrease pamiparib efficacy.
Other Chemotherapeutic Agents: Concurrent use may exacerbate hematological toxicities.
Anticoagulants and NSAIDs: Increased bleeding risk due to potential platelet count reduction.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.